Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$2.57 USD
+0.05 (1.98%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $2.59 +0.02 (0.78%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATHA 2.57 +0.05(1.98%)
Will ATHA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATHA
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Other News for ATHA
Director Kelly Romano Acquires 42,400 Shares of Athira Pharma Inc (ATHA)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Gilead Sciences (GILD) and Inspire Medical Systems (INSP)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), AbbVie (ABBV) and LENSAR (LNSR)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Athira Pharma (ATHA)
Buy Rating Affirmed for Athira Pharma Amid Promising Alzheimer’s Treatment Prospects